AR048003A1 - Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los c - Google Patents
Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los cInfo
- Publication number
- AR048003A1 AR048003A1 ARP050100928A ARP050100928A AR048003A1 AR 048003 A1 AR048003 A1 AR 048003A1 AR P050100928 A ARP050100928 A AR P050100928A AR P050100928 A ARP050100928 A AR P050100928A AR 048003 A1 AR048003 A1 AR 048003A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 26
- 238000000034 method Methods 0.000 title abstract 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 16
- 239000001257 hydrogen Substances 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 239000003638 chemical reducing agent Substances 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- -1 cyano, furyl Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Los compuestos de la formula (1) son antagonistas del receptor muscarínico. Composiciones farmacéuticas que contienen dichos compuestos, procesos e intermediarios para preparar dichos compuestos y la utilizacion de dichos compuestos para tratar afecciones pulmonares. Reivindicacion 1: Un compuesto de la formula (1), donde: a es 0 o un entero entre 1 y 5; cada R1 se selecciona en forma independiente entre C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C3-6 cicloalquilo, ciano, halo, -OR1a, - C(O)OR1b, -SR1c, -S(O)R1d, -S(O)2R1e y -NR1fR1g; cada uno de R1a, R1b, R1c, R1d, R1e, R1f y R1g es en forma independiente hidrogeno, C1-4 alquilo o fenilC1-4alquilo; b es 0 o un entero entre 1 y 4; cada R2 se selecciona en forma independiente entre C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C3-6 cicloalquilo, ciano, halo, -OR2a, -C(O)OR2b, -SR2c, -S(O)R2d, -S(O)2R2e y -NR2fR2g; cada uno de R2a, R2b, R2c, R2d, R2e, R2f y R2g es en forma independiente hidrogeno, C1-4 alquilo o fenilC1- 4alquilo; W representa O o NWa, donde Wa es hidrogeno o C1-4 alquilo; c es 0 o un entero entre 1 y 5; cada R3 representa en forma independiente C1-4 o dos grupos R3 se unen para formar C1-3 alquileno, C2-3 alquenileno o oxiran-2,3-diilo; m es 0 o 1; R4 es hidrogeno o C1-4 alquilo; r es un entero entre 2 y 4; R5 se selecciona entre hidrogeno, C1-4, -C(O)C1-4alquilo, -C1-4alquilenC(O)OR5a, -C(O)heterociclilo, -C(O)CH(NH2)(C1-4)alquilenQ, -(C1-4)alquilenC(O)Z, -C(O)(C1-4)alquilenZ, y -S(O)2(C1- 4)alquilenZ; donde Q es un sustituyente que contiene nitrogeno seleccionado entre -N5bR5c y heteroarilo; Z es un sustituyente que contiene nitrogeno seleccionado entre -NR5dR5e y heterociclilo; R5a es hidrogeno o C1-4 alquilo; cada uno de R5b, R5c, R5d y R5e representa en forma independiente hidrogeno, C1-4 alquilo, C3-6 cicloalquilo o hidroxifenilo, y donde C1-4 alquilo no está sustituido o está sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre amido, ciano, furilo, hidroxilo, y metilimidazolilo; el heterociclilo contiene 1 o 2 átomos de nitrogeno, y no está sustituido o está sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre hidroxilo, amido, C1-4 alcoxi, oxo, -S(O)2C1- 4alquilo, -(CH2)OC1-4alquilo, -C1-4alquilenOH, -NR5fR5g o -C(O)NR5hR5i, cada uno de R5f, R5g, R5h y R5i representa en forma independiente hidrogeno o C1-4 alquilo; y el heteroarilo contiene 1 o 2 átomos de nitrogeno; cada R6 representa en forma independiente C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C3-6 cicloalquilo, ciano, nitro, halo, N,N-di(C1-4)alquilamino(C2-4)alcoxi, -OR6a, -C(O)OR6b, -SR6c, -S(O)R6d, -S(O)2R6e o -NR6fR6g; cada uno de R6a, R6b, R6c, R6d, R6e, R6f y R6g es en forma independiente hidrogeno, C1-4 alquilo, C3-6 cicloalquilo, fenilo o fenilC1-4alquilo, donde cada grupo fenilo no está sustituido o está sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre halo, C1-4 alquilo y C1-4 alcoxi; y p es 0, 1 o 2; X1 se selecciona entre C1-3 alquileno, -C(O)C1-3alquileno, C1-3alquilenC(O)-, -SO2-, -SO2C1-3alquileno y C1-3alquilenSO2-; donde el grupo alquileno en cualquier X1 está opcionalmente sustituido con 1 o 2 sustituyentes seleccionados en forma independiente entre C1-4 alquilo y -NRxaRxb; donde Rxa y Rxb se selecciona en forma independiente entre hidrogeno y C1-4 alquilo; donde cada grupo alquilo y alcoxi en R1, R1a-1g, R2, R2a-2g, R3, R6 o R6a-6g, está opcionalmente sustituido con entre 1 y 5 sustituyentes fluoro; o una sal o un solvato o un estereoisomero aceptables para uso farmacéutico del mismo. Reivindicacion 21: Un proceso para preparar un compuesto de acuerdo con las reivindicaciones 1 y 16, caracterizada porque comprende: a) hacer reaccionar un compuesto de la formula (2), o una sal del mismo, con un compuesto de la formula (3), donde Z1 representa un grupo saliente, y P1 representa un átomo de hidrogeno o un grupo protector de hidroxilo; b) acoplar un compuesto de la formula (4), o un derivado reactivo del mismo, con un compuesto de la formula (5), donde P2 representa un átomo de hidrogeno o un grupo protector de hidroxilo; c) hacer reaccionar un compuesto de la formula (6), con un compuesto de la formula (7), donde Z2 representa un grupo saliente; y P3 representa un átomo de hidrogeno o un grupo protector de hidroxilo; d) hacer reaccionar un compuesto de la formula (2), con un compuesto de la formula (8), donde P4 representa un átomo de hidrogeno o un grupo protector de hidroxilo, en presencia de un agente reductor; o e) para un compuesto de la formula (1) en donde X1 representa C1-3 alquileno, hacer reaccionar un compuesto de la formula (6) con un compuesto de la formula (9), donde X1a representa un enlace o C1-2 alquileno; y P5 representa un átomo de hidrogeno o un grupo protector de hidroxilo, en presencia de un agente reductor; f) hacer reaccionar un compuesto de la formula (10), con un compuesto de la formula (11), donde P6 representa un átomo de hidrogeno o un grupo protector de hidroxilo, en presencia de un agente reductor; g) para un compuesto de la formula (1) en donde m es 0, hacer reaccionar un compuesto de la formula (2), con un compuesto de la formula (12), donde P7 representa un átomo de hidrogeno o un grupo protector de hidroxilo, y luego h) eliminar cualquier grupo protector P1, P2, P3, P4, P5, P6 o P7 para dar un compuesto de la formula (1). Reivindicacion 25: Un método para estudiar un sistema o muestra biologica caracterizado porque comprende un receptor muscarínico que comprende: a) poner en contacto el sistema o muestra biologica con un compuesto de las reivindicaciones 1 a 16; y b) determinar los efectos causados por el compuesto en el sistema o muestra biologica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55242104P | 2004-03-11 | 2004-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048003A1 true AR048003A1 (es) | 2006-03-15 |
Family
ID=34963851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100928A AR048003A1 (es) | 2004-03-11 | 2005-03-10 | Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los c |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7569588B2 (es) |
| EP (1) | EP1723111A1 (es) |
| JP (1) | JP2008532921A (es) |
| AR (1) | AR048003A1 (es) |
| MY (1) | MY145536A (es) |
| TW (1) | TW200538095A (es) |
| WO (1) | WO2005087732A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2005087735A1 (en) * | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7560469B2 (en) | 2004-03-11 | 2009-07-14 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7262205B2 (en) * | 2004-03-11 | 2007-08-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7524962B2 (en) * | 2004-03-11 | 2009-04-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528412A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物 |
| US7869588B2 (en) * | 2004-05-03 | 2011-01-11 | Somatek | System and method for providing particularized audible alerts |
| TW200714587A (en) * | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006099167A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7629336B2 (en) * | 2005-03-10 | 2009-12-08 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7659403B2 (en) * | 2005-03-10 | 2010-02-09 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US20060205949A1 (en) * | 2005-03-10 | 2006-09-14 | Theravance, Inc. | Crystalline forms of a biphenyl compound |
| EP1856049A1 (en) * | 2005-03-10 | 2007-11-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7728144B2 (en) * | 2005-06-13 | 2010-06-01 | Theravance, Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| CA2678193A1 (en) | 2007-02-09 | 2008-08-14 | Astellas Pharma Inc. | Aza-bridged-ring compound |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| CN114929697A (zh) | 2019-11-13 | 2022-08-19 | 日本新药株式会社 | 氮杂苯并咪唑化合物和药物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| KR970701174A (ko) | 1994-02-10 | 1997-03-17 | 오노다 마사요시 | 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same) |
| SG80041A1 (en) | 1998-06-08 | 2001-04-17 | Advanced Medicine Inc | Muscarinic receptor antagonists |
| US6693202B1 (en) | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| CA2392028C (en) * | 1999-12-07 | 2009-08-18 | Theravance, Inc. | Carbamate derivatives having muscarinic receptor antagonist activity |
| HUP0303529A3 (en) | 2000-12-22 | 2008-03-28 | Almirall Ag | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use |
| US6656694B2 (en) | 2001-01-11 | 2003-12-02 | Theravance, Inc. | Method for identifying a ligand for a biological substrate |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| UY27927A1 (es) | 2002-08-06 | 2003-12-31 | Glaxo Group Ltd | Antagonistas del receptor muscarínico m3 de acetilcolina |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CA2543858C (en) | 2003-11-21 | 2014-04-15 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7560469B2 (en) | 2004-03-11 | 2009-07-14 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7262205B2 (en) | 2004-03-11 | 2007-08-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528412A (ja) | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物 |
| EP1723109A1 (en) * | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7524962B2 (en) | 2004-03-11 | 2009-04-28 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2005087735A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006099167A1 (en) * | 2005-03-10 | 2006-09-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| TW200714587A (en) | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1856049A1 (en) | 2005-03-10 | 2007-11-21 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
-
2005
- 2005-01-31 TW TW094102900A patent/TW200538095A/zh unknown
- 2005-03-10 AR ARP050100928A patent/AR048003A1/es unknown
- 2005-03-10 US US11/077,224 patent/US7569588B2/en active Active
- 2005-03-10 EP EP05729943A patent/EP1723111A1/en not_active Withdrawn
- 2005-03-10 JP JP2007503011A patent/JP2008532921A/ja not_active Withdrawn
- 2005-03-10 WO PCT/US2005/007987 patent/WO2005087732A1/en not_active Ceased
- 2005-03-10 MY MYPI20051009A patent/MY145536A/en unknown
-
2009
- 2009-03-12 US US12/402,665 patent/US7858792B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200538095A (en) | 2005-12-01 |
| US20050203083A1 (en) | 2005-09-15 |
| WO2005087732A1 (en) | 2005-09-22 |
| US20090176767A1 (en) | 2009-07-09 |
| JP2008532921A (ja) | 2008-08-21 |
| US7569588B2 (en) | 2009-08-04 |
| US7858792B2 (en) | 2010-12-28 |
| EP1723111A1 (en) | 2006-11-22 |
| MY145536A (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048003A1 (es) | Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los c | |
| AR048032A1 (es) | Compuestos de bifenilo utiles como antagonistas de receptores muscarinicos, un proceso para su preparacion, composiciones farmaceuticas que los contienen, su uso en la fabricacion de un medicamento para el tratamiento de afecciones pulmonares y un metodo para estudiar una muestra biologica que los c | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR076838A1 (es) | Sulfonamidas nematocidas | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
| AR084408A1 (es) | Compuestos de purina y 7-deazapurina substituidos | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR078012A1 (es) | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus | |
| AR040870A1 (es) | Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende | |
| AR083933A1 (es) | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak | |
| RU2013124812A (ru) | Зонд, визуализирующий белок тау | |
| AR072488A1 (es) | Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas. | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| CY1108445T1 (el) | Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR035815A1 (es) | Derivados de piperidina, un proceso para su preparacion, composiciones y combinaciones farmacéuticas que comprenden a dichos derivados | |
| AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR086792A1 (es) | Compuestos para el tratamiento de la adiccion | |
| AR076645A1 (es) | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |